Medidata, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, is kicking off NEXT New York 2024, its premier life sciences conference. Uniting more than ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

AstraZeneca also said on Tuesday, along with its partner Daiichi Sankyo, it has submitted a new biologics license application ...

Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol.

Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. Delytact ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

8316.T Sumitomo Mitsui Financial Group, Inc.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Aileen Lamb hopes the approval of a new cancer treatment drug will give patients 'hope', after she was given the all clear ...